SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending sharply lower after announcing that Marvell canceled all purchase orders inherited from its acquisition of Celestial AI due to an alleged breach of confidentiality. Investors and community members are expressing significant frustration over management's handling of the disclosure, leading to widespread speculation about the company's future contracts and immediate valuation.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a focal point for investors as they await topline Phase 3 data from the HAELO trial, which the community sees as a potential validation for their in vivo CRISPR platform. Traders are actively debating the high short interest and the stock's susceptibility to a squeeze, with many weighing the clinical promise of a functional HAE cure against the broader volatility affecting the biotech sector.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending as investors weigh strong AI and automotive growth potential against near-term headwinds like supply chain constraints and cautious analyst sentiment. The stock is a primary focus for the community, which remains divided on whether the current price represents a buying opportunity or a deeper structural decline.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is experiencing significant bullish momentum driven by heavy short interest and mounting anticipation for its acquisition of Northern Data, which effectively expands its cloud and GPU infrastructure. The community is actively discussing a potential short squeeze, citing record-high short interest and strong backing from strategic partner Tether as catalysts for a potential rally.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is experiencing significant market movement driven by speculative interest in its shift toward custom AI chip design and high-performance server CPUs. Community discussions are split between euphoria over its long-term potential as an AI infrastructure backbone and intense debate regarding its valuation, with many traders actively debating the merits of aggressive shorting versus holding for a potential parabolic breakout.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is drawing significant investor interest as it approaches a high-profile oral presentation of pancreatic cancer data at Digestive Disease Week, which the community views as a critical catalyst for the stock. Traders are actively accumulating shares, citing strong scientific momentum and the company's progress in expanding global clinical trials.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares is experiencing massive volatility and bullish momentum driven by a strong semiconductor sector rally, fueled by earnings optimism and ongoing AI infrastructure spending. Investors are actively debating whether the current parabolic price action signifies a sustainable super-cycle or a speculative bubble, leading to intense sentiment clashes between bullish 'diamond hands' and traders betting on a sharp mean reversion.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences is currently seeing significant investor attention driven by positive Phase 3 acne data and the potential for its FASN inhibitor denifanstat as a cornerstone MASH treatment. The community is actively debating the company's valuation, the strategic shift toward combination therapies, and the high probability of a future buyout given the surge in M&A activity within the metabolic disease sector.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

The Direxion Daily Semiconductor Bear 3X Shares (SOXS) is seeing intense volatility and record-breaking volume as traders debate whether the semiconductor sector's prolonged winning streak represents an unsustainable AI bubble or a resilient super-cycle. Community sentiment remains deeply polarized between aggressive short-sellers betting on a mean reversion and bulls who argue that relentless momentum and capital rotation into chip-related infrastructure make shorting the sector a high-risk trade.

X-Energy, Inc. operates as an energy company The firm focuses on modular nuclear reactors and fuel technology for clean energy generation. The company was founded by Kam Ghaffarian and Eben Mulder on 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-energy Inc

X-energy is generating significant investor buzz as it makes its market debut, with the community highlighting its strategic backing from major players like Amazon and Dow to address the surging energy demands of AI data centers. Traders are actively debating the company's valuation and long-term potential compared to other modular nuclear reactor peers, fueled by high initial demand and its positioning as a key player in the clean energy infrastructure space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Polaris Capital Management LLC Has $35.80 Million Position in Lantheus Holdings, Inc. $LNTH

Polaris Capital Management LLC trimmed its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 15.6% in the fourth quarter, according to the company in its most recent Form...

Truist Financial Increases Lantheus (NASDAQ:LNTH) Price Target to $98.00

Truist Financial increased their target price on Lantheus from $89.00 to $98.00 and gave the stock a "buy" rating in a research report on Wednesday...

Lantheus Holdings, Inc. $LNTH Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC decreased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 89.3% during the 4th quarter, according to its most recent...

Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) have received an average rating of "Moderate Buy" from the eleven research firms that are currently covering the firm, MarketBeat...

Assenagon Asset Management S.A. Trims Position in Lantheus Holdings, Inc. $LNTH

Assenagon Asset Management S.A. lowered its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 94.4% during the fourth quarter, according to the company in its most recent...

Lantheus (NASDAQ:LNTH) Rating Increased to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Lantheus from a "buy" rating to a "strong-buy" rating in a report on Saturday...

CWA Asset Management Group LLC Makes New $1.67 Million Investment in Lantheus Holdings, Inc. $LNTH

CWA Asset Management Group LLC purchased a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 25,096 shares of the medical equipment p...

Lantheus Holdings, Inc. (LNTH) said on Tuesday that the U.S. Food and Drug Administration has extended its review of LNTH-2501 by three months.Shares of the company slipped marginally after hours at the time of writing.<h2 class="st-heading-2">Why The Delay?</h2>The agency is now slated to decide on the radiopharmaceutical-focused company’s application seeking approval for the diagnostic kit by June 29. The extended deadline is expected to give the agency additional time to review and consider further manufacturing related information submitted by Lantheus, it said.The extension, however, is not related to the efficacy or safety data of LNTH-2501, a radioactive diagnostic kit for for use with positron emission tomography (PET) for detecting somatostatin receptor positive neuroendocrine tumors in adults as well as pediatric patients, the company added.LNTH-2501 is not available in the U.S. yet.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around LNTH stock stayed within the ‘extremely bearish’ territory while message volume fell from ‘high’ to ‘normal’ levels.According to data from Koyfin, the 12-month average price target on the stock is at $91, representing a potential upside of about 13%. Of the 13 analysts covering the stock, 11 rate it ‘Buy’ or higher while two rate it a ‘Hold.’Earlier this month, Lantheus announced that the FDA approved its PYLARIFY TruVu injection. The injection is indicated for imaging certain lesions in men with prostate cancer, the second most common form of cancer affecting men in the U.S. It is now expected to be commercially available in the fourth quarter of 2026.<a href="https://stocktwits.com/symbol/LNTH">LNTH stock</a> has slipped 22% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/lulu-shares-fall-despite-board-reshuffle-as-2026-outlook-misses-street-expectations/cZ3EZeyRIXz">LULU Shares Fall Despite Board Reshuffle As 2026 Outlook Misses Street Expectations</a>Get updates to this developing story directly on Stocktwits.

In this photo illustration, the Lantheus Holdings logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Lantheus Says FDA Pushed Deadline For Reviewing Its Tumor Diagnostic Kit Application

LNTH Stock - Lantheus Holdings, Inc. (LNTH) said on Tuesday that the U.S. Food and Drug Administration has extended its review of LNTH-2501 by three months.

Equity

The agency is now slated to decide on the company’s application seeking approval for the diagnostic kit by June 29.


Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Average Recommendation of "Moderate Buy" by Analysts

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten ratings firms that are currently covering the stock, MarketBeat Ratings reports...

Lantheus (NASDAQ:LNTH) Lowered to Buy Rating by Wall Street Zen

Wall Street Zen lowered shares of Lantheus from a "strong-buy" rating to a "buy" rating in a research note on Sunday...

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America. The company was founded in 1956 and is headquartered in Bedford, MA.

LNTH
Lantheus Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LNTH News

LNTHLantheus Holdings Inc